ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

Breast Cancer Action Plan Committee Outrages By Plans for $14M In NCI Funds

August 1, 1997

Review Group Urges Increased Funding For NCI AIDS Drug Discovery Program

December 3, 1999

In Brief: ESMO Names Annual Award Winners

October 10, 2014

US Appeals Court Dismisses Fisher’s Privacy Act Suit Supporting Femara

January 10, 1997

Opening Shots Fired In 10 Year Defense of Cancer Program, Launching Of Effort To Continue, Expand It

September 19, 1980

In Brief: Arkansas, Iowa Appoint Center Directors; Broder Moves To Gene Sequencing Venture

August 14, 1998